Oncology

News

Astellas' Padcev and Gilead's Trodelvy grab key EU approvals

New approvals in the EU for Astellas' Padcev and Gilead's Trodelvy break new ground in the treatment of bladder and triple-negative breast cancer.

News

Image of a pair of lungs on an orange-beige background

Pfizer's Seagen-derived ADC pipeline suffers a setback

One of the antibody-drug conjugates at the heart of Pfizer's $43bn acquisition of Seagen three years ago has failed a phase 3 lung cancer trial.

News

CARSgen bags world-first approval for solid tumour CAR-T

CARSgen Therapeutics has claimed approval in China for gastric cancer therapy satri-cel, the first CAR-T to be cleared for a solid tumour.

Oncology

ASCO 2026 reshapes oncology trial design

The American Society of Clinical Oncology 2026 annual meeting showcased how, across tumour types, new cancer therapies are achieving deeper responses, extending survival and increasingly mo

News

Boehringer advances duo for aggressive cancers into phase 3

Boehringer Ingelheim steps up its push into oncology with phase 3 trials for pathfinder product Hernexeos and obrixtamig in hard-to-treat cancers.

Oncology

Liquid biopsy and the future of tumour-agnostic treatments

Liquid biopsy-based tools are positioned as a critical enabler of tumour-agnostic therapeutic development.

Astellas' Padcev and Gilead's Trodelvy grab key EU approvals

Pfizer's Seagen-derived ADC pipeline suffers a setback

CARSgen bags world-first approval for solid tumour CAR-T

ASCO 2026 reshapes oncology trial design

Boehringer advances duo for aggressive cancers into phase 3

Liquid biopsy and the future of tumour-agnostic treatments

Beacon's XLRP gene therapy set for filing after phase 3 win

Discover a new era of healthcare panel engagement: Grounded ...

Oncology

Editor's Picks